• Endovascular Engineering

  Participated · Series C · Apr 2026

  E2 is commercializing the Hēlo® Thrombectomy Platform, designed with a patented dual-action mechanism that integrates aspiration with mechanical clot disruption to deliver large-bore performance through a small-profile catheter. The system is indicated for non-surgical removal of emboli and thrombi from pulmonary arteries and venous vasculature and supports injection, infusion, and aspiration during procedures. E2 describes the platform as intended to improve procedural efficiency and clinical performance as mechanical thrombectomy adoption grows. With the oversubscribed $80 million Series C, the company plans to scale its commercial organization and continue investments in research and operations. The company is backed by a syndicate including Gilde Healthcare, Norwest, Santé Ventures, 415 Capital, S3 Ventures, Panakès Partners, and M&L Healthcare Investments. New board members from the lead investors will join as the company advances commercialization.

• HEPTA Medical

  Participated · Series A · Apr 2026

  HEPTA Medical develops a device that integrates a minimally invasive thermal ablation probe introduced via natural orifices to destroy early lung tumors by heat. The company highlights a large unmet need given more than 2.2 million new lung cancer cases and roughly 1.8 million deaths annually worldwide. Founded in 2019 and based in Suresnes, HEPTA employs around a dozen people. Financially, it has just closed a €10 million Series A to fund growth and hiring. The startup plans to initiate its first clinical trials in the second quarter of 2026. Its investor base includes UI Investissement and Supernova Invest as new participants alongside Bpifrance, M & L, Sofinnova Partners, Cléry and MD Start.

• SafeHeal

  Participated · Series C · Sep 2025

  SafeHeal SAS, together with its U.S. subsidiary SafeHeal Inc., designs and develops Colovac, a flexible endoluminal bypass sheath intended to shield the anastomotic site from fecal matter following colorectal surgery. The device remains in place for roughly 10 days and is later removed endoscopically, sparing patients a second surgical intervention and the lifestyle burdens of an ostomy bag. Colovac is currently limited to investigational use in the United States under an IDE study, while commercialization efforts are focused on the European Union. The newly raised capital will accelerate the U.S. pivotal IDE trial and fund EU commercial launch preparations. SafeHeal’s Series C round was initially €35 million and has now been extended, demonstrating strong investor interest. Although the company has not disclosed revenue or user metrics, its financing momentum underscores market confidence in the potential clinical and economic benefits of Colovac.

• FastWave Medical

  Participated · Equity · Dec 2024

  FastWave Medical is a Brooklyn Park, Minnesota–based medtech startup creating a surgical device intended to simplify and improve procedures for patients with severe arterial disease. Co-founded and led by CEO Scott Nelson, the company’s core product is still under development; specific clinical or commercial metrics have not yet been disclosed. In 2021 the company secured a $12 million strategic investment from China-based Grand Pharmaceutical Group to advance its R&D and regulatory pathway. Since that financing, Grand Pharmaceutical has withheld further capital and declined to cooperate with a required regulatory filing that would let FastWave bring in new investors. As a result, FastWave is now navigating that regulatory process on its own while fielding interest from additional backers. Nelson has also expressed concern that Grand’s parallel investment in a Chinese firm developing similar technology could jeopardize FastWave’s intellectual property and competitive position. The company’s immediate focus is resolving the legal hurdles so it can reopen fundraising and continue product development toward clinical and commercial milestones.

• CorFlow Therapeutics AG

  Participated · Series B · Sep 2024

  CorFlow Therapeutics is developing the CoFl system to provide timely, accurate detection of microvascular obstruction (MVO) in the cath lab immediately after stent implantation and to enable localized delivery of therapeutics to the microvasculature. The technology integrates with standard guide catheter and wire access and is intended to both diagnose MVO and deliver treatments at the point of care. CorFlow has reported recent data from over 70 patients in its first-in-human MOCA I trial and an extensive preclinical program supporting its approach. The company plans a MOCA II pivotal IDE trial in the US and Europe to validate CoFl against contrast-enhanced cardiac MRI and to support US market clearance. It will also run an adaptive platform therapy study in Europe to evaluate multiple therapeutic agents delivered via CoFl and measure clinical and imaging outcomes up to six months. Headquartered in Baar, Switzerland and founded in 2016, CorFlow is collaborating with academic partners including the University of Bern, ETH Zurich and University Hospital Zurich. CorFlow Therapeutics develops the Controlled Flow Infusion (CoFITM) system and a proprietary dynamic Microvascular Resistance (dMVRTM) concept to detect and treat microvascular obstruction (MVO) in the cathlab. The CoFITM system is positioned as a combined diagnostic and therapeutic technology that enables detection and low-flow infusion treatment of MVO immediately after reopening epicardial arteries. Seed proceeds will finance the First-in-Man MOCA I (MVO with CoFITM System Assessment) safety and feasibility trial in 40 acute heart attack patients. MOCA I will measure peri-procedural dMVR and compare those values to post-procedure contrast-enhanced MRI, and will investigate low-flow infusion of approved therapeutic agents to reduce MVO. The company cites that around 50% of acute heart attack patients develop MVO, translating to roughly 200,000 patients annually, and notes MVO is an independent predictor of heart failure and death. CorFlow has presented nonclinical data at major cardiology meetings (ACC, EuroPCR, ESC) and plans further presentation at TCT; it aims to raise a Series A in 2019 to secure longer-term R&D, clinical, and regulatory activities. CorFlow Therapeutics is developing proprietary technologies to diagnose and treat microvascular obstructions (MVO) in severe heart attack patients. Its technologies aim to enable interventional cardiologists to diagnose and treat MVO, potentially reducing short- and long-term complication rates. The company is led by CEO and co-founder Jon H. Hoem. Headquartered in Baar, Switzerland, CorFlow has raised more than CHF5M in seed funding to date. It completed a CHF 2.6M first close of a Seed+ round to advance clinical development. The company plans to use the funds to finance the 80-patient First-in-Man MOCA (MVO with CoFI™ System Assessment) clinical trial in Europe and intends the Seed+ as the basis for a larger Series A to secure long-term R&D, clinical, and regulatory activities.

No current team members are available.